225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks. (May 2019)

• Record Type: Journal Article
• Authors: Usmani, Sharjeel; Rasheed, Rashid; Al kandari, Fareeda; Marafi, Fahad; Naqvi, Syed Ali Raza
• Is Part Of: Clinical nuclear medicine. Volume 44:Number 5(2019)
• Publication Date: 2019-05
• Subjects: 225Ac-PSMA-617 -- α therapy -- metastatic castration-resistant prostate cancer; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002525
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: 225 Ac-based PSMA-targeted therapy has emerged as promising agent for the treatment of metastatic castration-resistant prostate cancer. Posttherapy image is used for tracer localization and dosimetry. Prior 2 photopeaks of 440 and 218 KeV were reported for posttherapy imaging. Our study of gamma ray spectrum, phantom, and clinical images show that imaging with 3 major photopeaks of 78, 218, and 440 KeV gives better quality images, high count statistics, and higher number of lesion delineations. It is therefore suggested that posttherapy imaging may be carried out using 3 major abundant photopeaks.